Impaired humoral immunity in treated Hodgkin's disease
- PMID: 301608
- DOI: 10.1056/NEJM197708042970504
Impaired humoral immunity in treated Hodgkin's disease
Abstract
To define the contribution of aggressive lymphoma treatment to the risk of post-splenectomy septicemia, we investigated the humoral immunity of 44 patients with Hodgkin's disease. Specific antibody against Haemophilus influenzae Type b was significantly reduced (mean, 147 ng per milliliter, P less than 0.01) in patients receiving combined treatment (radiotherapy and chemotherapy), whereas single treatment reduced titers marginally (chemotherapy) or not at all (radiotherapy). Untreated patients had normal values (396 ng per milliliter), and splenectomy was without effect. In some patients who received combined treatment, titers were reduced to levels seen in infants. IgM levels were likewise normal in untreated patients. Chemotherapy, however, significantly reduced IgM levels (P less than 0.025), an effect potentiated by prior splenectomy. IgG, IgA, alternate-pathway activity, C3, C4 and CH50 were all normal or elevated. Aggressive treatment with chemotherapy and radiation impairs humoral defense against encapsulated micro-organisms, and thus magnifies the risk of post-splenectomy septicemia in patients with Hodgkin's disease.
Similar articles
-
Impaired antibody response to pneumococcal vaccine after treatment for Hodgkin's disease.N Engl J Med. 1978 Aug 31;299(9):442-8. doi: 10.1056/NEJM197808312990903. N Engl J Med. 1978. PMID: 28483
-
Coexistent yellow nail syndrome and selective antibody deficiency.Ann Allergy Asthma Immunol. 2003 Nov;91(5):496-500. doi: 10.1016/S1081-1206(10)61521-9. Ann Allergy Asthma Immunol. 2003. PMID: 14692436
-
The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.Haematologica. 1998 Sep;83(9):812-23. Haematologica. 1998. PMID: 9825578
-
Nonmalignant complications of therapy for Hodgkin's disease.Hematol Oncol Clin North Am. 1989 Jun;3(2):331-43. Hematol Oncol Clin North Am. 1989. PMID: 2663831 Review.
-
[Changes in concentrations of IgM, IgA and IgM immune globulins after megavolt therapy with the large-field technic in patients with Hodgkin's disease].Strahlenther Onkol. 1988 Jun;164(6):323-9. Strahlenther Onkol. 1988. PMID: 3133799 Review. German.
Cited by
-
Long-term complications of laparotomy in Hodgkin's disease.Ann Surg. 1994 Jun;219(6):615-21; discussion 621-4. doi: 10.1097/00000658-199406000-00004. Ann Surg. 1994. PMID: 8203970 Free PMC article. Review.
-
Acute-phase-proteins and parameters of humoral immunity in patients with advanced Hodgkin's disease.J Cancer Res Clin Oncol. 1985;110(1):65-70. doi: 10.1007/BF00402504. J Cancer Res Clin Oncol. 1985. PMID: 2410428 Free PMC article.
-
Circulating immune complexes, complement and complement component levels in childhood Hodgkin's disease.Clin Exp Immunol. 1980 Mar;39(3):551-61. Clin Exp Immunol. 1980. PMID: 7379328 Free PMC article.
-
The overwhelming postsplenectomy sepsis problem.World J Surg. 1980 Jul;4(4):423-32. doi: 10.1007/BF02393164. World J Surg. 1980. PMID: 7015698 No abstract available.
-
Immunity in Hodgkin's disease: status after 10 years remission.Br J Cancer. 1990 Aug;62(2):324-5. doi: 10.1038/bjc.1990.287. Br J Cancer. 1990. PMID: 2386752 Free PMC article. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous